Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Multiple Myeloma 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Recurrence 28Leukemia 24Vomiting 23Neoplasms, Plasma Cell 20Lymphoma 18Neoplasms 16Nausea 13Burkitt Lymphoma 11Prostatic Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Follicular 5Lung Neoplasms 5Hodgkin Disease 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Paraproteinemias 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

pembrolizumab 95Cisplatin 35Paclitaxel 27Carboplatin 27Docetaxel 17lenvatinib 15Fluorouracil 14Saline Solution 13Capecitabine 12Pemetrexed 10Gemcitabine 10Oxaliplatin 9Cetuximab 7Albumin-Bound Paclitaxel 7olaparib 6epacadostat 6Bevacizumab 6130-nm albumin-bound paclitaxel 6Leucovorin 5enzalutamide 4Etoposide 4trifluridine tipiracil drug combination 3regorafenib 3belzutifan 3Prednisone 3Irinotecan 3Glucose 3Dexamethasone 3liposomal doxorubicin 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Dexamethasone × Clear all
NCT03834506 2025-07-18

KEYNOTE-921

Merck Sharp & Dohme LLC

Phase 3 Completed
1,030 enrolled 24 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04907227 2024-07-12

KEYNOTE-921

Merck Sharp & Dohme LLC

Phase 3 Terminated
81 enrolled 19 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03950674 2024-06-10

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
40 enrolled 20 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡